For the quarter ended December 31, 2025, the SMA outperformed the Index on both a gross- and net-of-fees basis due to ...
For 4Q25, Macquarie Balanced Fund Institutional Class shares underperformed the Fund’s equity benchmark, the S&P 500 Index. Read more here.
GOOGL’s encore for that record peak of $340.49 on Wednesday was three-straight losses to end the week with only a 0.4% gain ...
Eli Lilly and Co (NYSE: LLY) has outperformed the market over the past 5 years by 25.43% on an annualized basis producing an average annual return of 37.44%. Currently, Eli Lilly and Co has a market ...
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case ...
Is the Magnificent 7 finished? NVDA shines while Tesla struggles and Eli Lilly surges, as Zacks Market Edge debates who stays, who goes in 2026.
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
The investment bank said many companies faced thesis-changing Phase 3 readouts this year, with outcomes that could materially reshape valuations regardless of the broader macro backdrop. But UBS also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback